Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

Status Completed

Clinical Trial Summary

Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success.

This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received HCT since 1990, or who will undergo Hematopoietic cell transplant (HCT) during the study period. The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease correction and ultimate benefit from HCT and the cross-sectional portion of the study will assess the benefit of HCT 2 years post-HCT in consenting surviving patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02064933
Study type	Observational
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase
Start date	February 2, 2014
Completion date	May 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01652092` - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	N/A
Completed	`NCT01953016` - Participation in a Research Registry for Immune Disorders
Active, not recruiting	`NCT02333760` - Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome	Phase 1/Phase 2
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT04371939` - Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome	Phase 2
Completed	`NCT01347346` - Gene Therapy for WAS	Phase 1/Phase 2
Completed	`NCT00160355` - Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome	Phase 1
Recruiting	`NCT01821781` - Immune Disorder HSCT Protocol	Phase 2
Completed	`NCT01289847` - A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency	Phase 4
Completed	`NCT01347242` - Gene Therapy for Wiskott-Aldrich Syndrome (WAS)	Phase 1/Phase 2
Terminated	`NCT00006054` - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies	N/A
Enrolling by invitation	`NCT03198195` - Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome	N/A
Recruiting	`NCT03019809` - A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients	Phase 2
Terminated	`NCT00909363` - Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients	Phase 2
Enrolling by invitation	`NCT01852370` - Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases	Phase 1/Phase 2
Completed	`NCT03513328` - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation	Phase 1/Phase 2
Active, not recruiting	`NCT01410825` - Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome	Phase 1/Phase 2
Active, not recruiting	`NCT00004341` - Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders	N/A
Completed	`NCT03399461` - Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)